Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
November 04, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
August 12, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
May 17, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
March 30, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
March 23, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity
March 04, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
January 28, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the...
Official_Bellicum_Logo_RGB.jpg
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
December 10, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
December 07, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
November 05, 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common...